Real-life data on the efficacy and safety of letermovir for cytomegalovirus prophylaxis in high-risk pediatric patients: a single-center analysis.

ABSTRACT:

Background

Letermovir (LET) is approved for the prophylaxis of cytomegalovirus (CMV) infection and disease in adult hematopoietic stem cell transplantation (HSCT) patients up to day 100. The use of LET in the pediatric HSCT population lacks extensive real-world research, especially for high-risk pediatric patients with CMV reactivation. The aim of our study was retrospectively analyzed the efficacy and safety of LET in high-risk pediatric patients with CMV activation, and conducted a preliminary exploration of its duration of use.

Methods

This was a single-center, retrospective study. A total of 123 patients under 18 years of age who were at high risk of CMV reactivation were included, with 61 of them receiving LET for prophylaxis. The median duration was 100 days (ranging f

SUBMITTER: Zhang M 

PROVIDER: S-EPMC12433127 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature